Recode Health Ventures is a San Francisco-based venture capital firm founded in 2022, focused on transforming the healthcare sector through innovative technologies. The firm's founders are dedicated to revolutionizing healthcare by leveraging exponential technologies to improve patient outcomes and streamline healthcare delivery. By identifying and supporting emerging companies within the healthcare space, Recode Health Ventures aims to foster advancements that address critical challenges in the industry.
LabGenius Ltd is a biopharmaceutical company based in London, United Kingdom, focused on discovering and developing new protein therapeutics to address unmet medical needs, including conditions like Inflammatory Bowel Disease. Founded in 2012, the company utilizes a machine learning-driven evolution engine and a robotic platform known as EVA, which is capable of designing, conducting, and learning from its own experiments. This innovative approach integrates advanced technologies from synthetic biology, robotics, and machine learning, enabling the engineering of protein drugs with enhanced properties such as protease stability and tissue penetration. By leveraging these cutting-edge methodologies, LabGenius aims to provide physicians with access to novel protein therapeutics that are developed through automation and intelligent design.
Verisian
Pre Seed Round in 2023
Accelerate drug time to market through real study traceability and unparalleled trial integrity
Sensible Biotechnologies
Pre Seed Round in 2023
Operator of a cell-based biotechnology platform designed to produce messenger ribonucleic acid(mRNA) therapeutics and vaccines. The company's platform uses cell engineering, computational biology, and precision fermentation to optimize the production of vaccinia capping enzymes, enabling medical professionals to provide optimal medicines to their patients.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.